RMD

What is RMD?

ResMed started back in 1989 when Peter Farrell took a gamble on commercializing a prototype for treating sleep apnea. Since then, the company has grown from a niche Australian startup into a San Diego-based global leader in respiratory medicine. Their core business model focuses on creating a seamless ecosystem for patients with chronic conditions like obstructive sleep apnea and COPD. They do this by combining high-quality hardware with cloud-based software that allows doctors and patients to track health data in real time.

Their product lineup is led by the AirSense series of CPAP machines and various ergonomic mask interfaces. Beyond the physical hardware, ResMed has built a massive software-as-a-service business through key acquisitions like Brightree and MatrixCare. These platforms help out-of-hospital care providers manage their workflows more efficiently. Historically, the company hit its biggest stride around 2014 when it committed fully to cloud connectivity. This move turned them from a simple equipment manufacturer into a data-driven digital health powerhouse with millions of connected devices worldwide.

Financially, ResMed is in a solid spot. They have historically enjoyed high margins and strong cash flow, which has allowed for consistent dividend growth. While they recently navigated some supply chain constraints and the ripple effects of a major competitor's recall, they managed to capture significant market share during that period. Their balance sheet remains robust enough to support ongoing research and development as well as strategic tuck-in acquisitions.

Looking toward 2026, the strategy is focused on AI integration and market expansion. While some investors worry about weight-loss drugs reducing the sleep apnea patient pool, ResMed views this as a potential tailwind for diagnosis. They plan to use AI to better identify undiagnosed patients and integrate their digital platforms with broader wellness management programs. The goal for 2026 is to have hundreds of millions of people benefiting from their digital health ecosystem, focusing on personalized, home-based care.

What is the XTRM Indicator?

The XTRM (Extreme) Indicator is a proprietary momentum indicator that measures cumulative time spent in extreme territory. Unlike traditional oscillators like RSI that measure a snapshot in time, XTRM accumulates how long an asset remains in oversold or overbought conditions, providing a deeper understanding of momentum exhaustion.

For RMD, monitoring the XTRM indicator provides valuable insights into prolonged extreme conditions. When the XTRM drops significantly below zero (especially below -125), ResMed Inc. has been in oversold territory for an extended period, suggesting potential for a reversal. Conversely, high positive XTRM values indicate extended overbought conditions.

Understanding RMD XTRM Signals

• Deep Oversold (XTRM below -125): When RMD XTRM falls below -125, it indicates prolonged time in extreme oversold conditions. This cumulative measure often provides stronger reversal signals than single-day oversold readings.
• Neutral Zone (XTRM near 0): When XTRM hovers around zero, RMD is in a balanced state without extended extreme conditions. This can indicate consolidation or indecision in the market.
• Overbought (XTRM above +10): An XTRM above +10 indicates RMD has been in overbought territory for an extended period, potentially signaling an overextended rally and increased risk of pullback.

Daily vs Weekly XTRM for RMD

This page displays both daily and weekly XTRM for RMD. The daily XTRM tracks short-term cumulative extremes, useful for identifying swing trading opportunities. The weekly XTRM provides a longer-term perspective on momentum exhaustion, helping investors spot major turning points.

By analyzing both timeframes together, you can identify when ResMed Inc. is experiencing extreme conditions at multiple time scales, which often leads to the strongest reversal setups.

Historical XTRM Extreme Analysis

Above, we track historical instances when RMD XTRM dropped below -125 (extreme oversold territory). These periods represent times when ResMed Inc. spent extended periods in oversold conditions, which historically have presented some of the best buying opportunities. Analyzing how RMD behaved after reaching these extreme XTRM levels can help inform future trading decisions.